Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.
Numerous mechanism-based anticancer drugs that target the phosphatidylinositol 3-kinase (PI3K) pathway are in clinical trials. However, it remains challenging to assess responses by traditional imaging methods. Here, we show for the first time the efficacy of hyperpolarized (13)C magnetic resonance spectroscopy (MRS) in detecting the effect of PI3K inhibition by monitoring hyperpolarized [1-(13)C]lactate levels produced from hyperpolarized [1-(13)C]pyruvate through lactate dehydrogenase (LDH) activity. In GS-2 glioblastoma cells, PI3K inhibition by LY294002 or everolimus caused hyperpolarized lactate to drop to 42 +/- 12% and to 76 +/- 5%, respectively. In MDA-MB-231 breast cancer cells, hyperpolarized lactate dropped to 71 +/- 15% after treatment with LY294002. These reductions were correlated with reductions in LDH activity to 48 +/- 4%, 63 +/- 4%, and 69 +/- 12%, respectively, and were associated with a drop in levels of LDHA mRNA and LDHA and hypoxia-inducible factor-1alpha proteins. Supporting these findings, tumor growth inhibition achieved by everolimus in murine GS-2 xenografts was associated with a drop in the hyperpolarized lactate-to-pyruvate ratio detected by in vivo MRS imaging, whereas an increase in this ratio occurred with tumor growth in control animals. Taken together, our findings illustrate the application of hyperpolarized (13)C MRS of pyruvate to monitor alterations in LDHA activity and expression caused by PI3K pathway inhibition, showing the potential of this method for noninvasive imaging of drug target modulation.
Department of Radiology and Biomedical Imaging , University of California at San Francisco, San Francisco, California 94158, USA.
Christopher S
CS
Ward
Humsa S
HS
Venkatesh
Myriam M
MM
Chaumeil
Alissa H
AH
Brandes
Mark
M
Vancriekinge
Hagit
H
Dafni
Subramaniam
S
Sukumar
Sarah J
SJ
Nelson
Daniel B
DB
Vigneron
John
J
Kurhanewicz
C David
CD
James
Daphne A
DA
Haas-Kogan
Sabrina M
SM
Ronen
D000818:Animals; D002247:Carbon Isotopes / Q000493:pharmacokinetics; D002867:Chromones / Q000494:pharmacology / Q000627:therapeutic use; D016503:Drug Delivery Systems; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000068338:Everolimus; D005909:Glioblastoma / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D019344:Lactic Acid / Q000493:pharmacokinetics; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D051379:Mice; D008819:Mice, Nude; D008991:Monitoring, Physiologic / Q000379:methods*; D009025:Morpholines / Q000494:pharmacology / Q000627:therapeutic use; D009369:Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D020123:Sirolimus / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
D002247:Carbon Isotopes; D002867:Chromones; D004791:Enzyme Inhibitors; D009025:Morpholines; D000081082:Phosphoinositide-3 Kinase Inhibitors; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D019344:Lactic Acid; D000068338:Everolimus; D020123:Sirolimus